Microsoft word - programme final web version.doc

Gastroenterology
Thursday 11 November 2010
Venue: Royal College of Physicians of Edinburgh, 9 Queen Street, Edinburgh Registration and Coffee
Welcome by Dr Mike Jones, Vice-President, Royal College of Physicians of Edinburgh
Session 1 – How do I manage
Chair: Dr David Nylander, Consultant Gastroenterologist, Sunderland Royal Hospital C Diff diarrhoea
Professor Chris Probert, Professor of Gastroenterology, Bristol Royal Infirmary ● epidemiology – incidence, morbidity and mortality, cost to NHS ● prevention – antibiotic regimes, isolation wards ● how do I manage metronidazole/standard dose vancomycin treatment failures? role of higher dose oral vanc, role of immunoglobulin, role of steroids Lower GI bleeding
Miss Sarah Mills, Consultant Colorectal Surgeon, Wansbeck General Hospital
● epidemiology ● investigation – who to refer for further investigation of rectal bleeding in the community. Is lower GI
investigation required in the acute setting? OGD? ● treatment options, what to do with those lower GI bleeds that keep
bleeding (i.e. embolisation/ laparoscopy and colonoscopy on table)? Current treatment strategies for anal fissures/
haemorrhoids
10.30 Fatty
Professor Christopher Day, Professor of Liver Medicine and Honorary Consultant Physician, University of Newcastle ● scale of the problem, fatty liver so what? natural history of disease ● strategy to identify patients already with some cirrhosis/at risk of developing cirrhosis – scoring systems/ fibroscans/ who to biopsy ● current treatment strategies and therapies on the horizon Coffee / tea
Session 2 – Ensuring patient safety
Chair: Dr Christian Dipper, Consultant Physician and Gastroenterologist, Royal Victoria Infirmary, Newcastle 10 years of anti-TNF therapy in IBD: what have we learnt?
Professor Jack Satsangi, Professor of Gastroenterology, University of Edinburgh
● what is the known safety profile? ● what are the unanswered questions? ● how to convey information responsibly?
● how to balance risks and efficacy?
Bones and steroids
Professor Juliet Compston, Professor of Bone Medicine, Addenbrooke’s Hospital. Cambridge
● what are the risks of developing osteopenia/osteoporosis/low trauma fractures if you are taking a) long term steroids
b) intermittent steroids but several times a year ● when and how frequently should we be dexa scanning these patients
● does Calcium supplementation when on steroids help, and to what extent?
12.30 Lunch
Gastroenterology
Thursday 11 November 2010
Venue: Royal College of Physicians of Edinburgh, 9 Queen Street, Edinburgh AFTERNOON
Session 3 – GI therapeutics avoiding waste
Chair: Dr Charles Lees, Consultant Gastroenterologist, Western General Hospital, Edinburgh 5 ASA drugs in Crohn’s disease
Dr Miles Parkes, Consultant Gastroenterologist, Addenbrooke's Hospital, Cambridge
● what is the evidence for ASA benefit in Crohn’s? ● is there a group of Crohn’s patients who may benefit? ● is it cost
effective?
13.45 Endoscopy
Dr Bjorn Rembacken, Consultant Gastroenterologist, General Infirmary, Leeds ● common pitfalls in endoscopy and polypectomy ● shortcomings of colonoscopy ● shortcomings of our Bowel Cancer Screening programme STANLEY DAVIDSON LECTURE
Chair: Dr Mike Jones, Vice-President, Royal College of Physicians of Edinburgh
Patient safety; how can revalidation help?
Mr Paul Philip, Deputy Chief Executive, General Medical Council

Symposium feedback / tea
Session 4 – New developments
Chair: Dr John Mansfield, Consultant Physician and Gastroenterologist, Royal Victoria Infirmary, Newcastle-upon-Tyne IBD genetics – translating science into practice
Dr Charles Lees, Consultant Gastroenterologist, Western General Hospital, Edinburgh
● review of recent history of IBD genetics ● is IBD a spectrum of several diseases and can the nature of IBD be
predicted /determined by genetics? could this help direct treatment in the future? can it inform prognosis?
Viral hepatitis – new treatments towards a cure
Dr Andrew Holt, Consultant Physician and Hepatologist, Queen Elizabeth Hospital, Birmingham
● current practice in management of Hep B/C, prevalence of treatment failures ● future drugs on the horizon – protease
inhibitors for HCV - results from preliminary trials, ?eltrombopag, ??fish oils, ??HCV vaccine
16.25 Close
For further details and to book online: http://events.rcpe.ac.uk

Source: http://events.rcpe.ac.uk/booking-forms/Programme_Final_Web_Version.pdf